Cabozantinib

• Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation Pending
  2024-518386-95-02 Phase II 1 country Fondazione Ricerca Traslazionale
• Intensified Monitoring of PhArmacology of Cabozantinib as a tool for Toxicity management in patients with renal cell carcinoma Pending
  2026-525267-40-00 Phase IV 1 country Centro Di Riferimento Oncologico Di Aviano
• SKIPP2: Cabozantinib Dose Skipping as an Alternative to Dose Reductions Recruiting
  2025-522962-58-00 Phase II 1 country Leids Universitair Medisch Centrum (LUMC)
• Randomized Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carc… Recruiting
  2024-515023-11-00 Phase III 8 countries Arcus Biosciences Inc.
• A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK-6482-033) Recruiting
  2024-517136-21-00 Phase III 12 countries Merck Sharp & Dohme LLC
• Digital monitoring of self-reported symptoms by patients treated with Cabozantinib plus Nivolumab for advanced clear-cell renal carcinoma: T… Recruiting
  2024-518991-30-00 Phase IV 1 country Centre Francois Baclesse
• CLINICAL AND HUMORAL IMPACT OF PRIMARY TUMOR ABLATION IN METASTATIC RENAL CELL CARCINOMA TREATED WITH IMMUNOTHERAPY.THE ITALIC-RCC RANDOMIZE… Recruiting
  2024-517789-41-00 Phase IV 1 country Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• Cabozantinib and Nivolumab among older patients with renal-cell carcinoma, a prospective cohort with geriatric, pharmacologic and patient-re… Recruiting
  2024-516650-22-00 Phase IV 1 country Institut Gustave Roussy
• CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Recruiting
  2023-503317-29-00 Phase III 10 countries Institut Gustave Roussy
• Immunological variables associated to ICI toxicity in cancer patients Recruiting
  2023-505360-11-00 Phase II 1 country Institut Jules Bordet
• PEMBROCABOSARC : Combination of pembrolizumab and cabozantinib in patients with advanced sarcomas Recruiting
  2023-509496-16-00 Phase II 1 country Institut Bergonie
• A Phase II trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP)… Recruiting
  2024-516612-16-00 Phase II 1 country Fondazione IRCCS Istituto Nazionale Dei Tumori
• Clinical trial evaluating the value of treatment with therapy specifically targeting the molecular alterations identified in the tumor of pa… Recruiting
  2023-510567-35-00 Phase II 1 country Centre Leon Berard
• Pan tumor Roll Over Study Recruiting
  2023-506914-32-00 Phase II 10 countries Bristol-Myers Squibb Services Unlimited Company
• Cabozantinib plus Durvalumab in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histolog… Recruiting
  2023-509821-29-00 Phase II 1 country Fondazione IRCCS Istituto Nazionale Dei Tumori
• DRUP trial Recruiting
  2023-509152-33-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• Treatment pause versus treatment continuation in good or intermediate risk with only one adverse prognostic factor in mRCC patients that has… Ended
  2024-514644-93-00 Phase III 1 country Centre Hospitalier Universitaire De Bordeaux
• Phase 3 Study of Belzutifan in Combination With Lenvatinib Versus Cabozantinib for Treatment of RCC Ended
  2024-510620-39-00 Phase III 13 countries Merck Sharp & Dohme LLC
• Study of Cabozantinib in Combination With Atezolizumab compared to Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castratio… Ended
  2024-516481-11-00 Phase III 9 countries Exelixis Inc.
• A Phase 3 Trial Comparing Selpercatinib to Cabozantinib or Vandetanib in Patients with RET-Mutant Medullary Thyroid Cancer Ended
  2023-506782-56-00 Phase III 9 countries Eli Lilly & Co.
• This is a randomized, double-blind, controlled trial to evaluate the efficacy and safety of cabozantinib in combination with nivolumab and i… Ended
  2024-515616-47-00 Phase III 9 countries Exelixis Inc.
• An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizu… Ended
  2023-506184-34-00 Phase III 11 countries F. Hoffmann-La Roche AG
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated… Ended
  2024-516478-31-00 Phase III 3 countries Exelixis Inc.
• A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced H… Ended
  2024-516479-34-00 Phase III 5 countries Exelixis Inc.

Showing 1–24 of 35 trials